Bicalutamide
- Generic Name
- Bicalutamide
- Brand Names
- Casodex
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14F4N2O4S
- CAS Number
- 90357-06-5
- Unique Ingredient Identifier
- A0Z3NAU9DP
- Background
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
- Indication
Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.
- Associated Conditions
- Metastatic stage D2 Prostatic carcinoma
- Associated Therapies
- -
Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2016-05-25
- Target Recruit Count
- 30
- Registration Number
- NCT00943956
- Locations
- 🇫🇷
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 1538
- Registration Number
- NCT00936390
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 182
- Registration Number
- NCT00884273
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Ospedali riuniti, Ancona, Italy
🇧🇪Institut Jules Bordet, Bruxelles, Belgium
🇫🇮KYS/kirurgian klin (Kuopio), Kuopio, Finland
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
- Conditions
- Interventions
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 52
- Registration Number
- NCT00878436
- Locations
- 🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸NYU Cancer Center, New York, New York, United States
🇺🇸North Shore University Hospital-Monter Cancer Center, Lake Success, New York, United States
Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 101
- Registration Number
- NCT00846976
- Locations
- 🇺🇸
Research Site, New York, New York, United States
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 246
- Registration Number
- NCT00833248
- Locations
- 🇬🇧
Kent Oncology Centre Maidstone Hospital, Maidstone, Kent, United Kingdom
🇫🇷Clinique du Parc, Toulouse, France
🇫🇷Centre de Lutte Contre le Cancer Nantes-Atlantique Centre René Gauducheau, Saint Herblain Cedex, France
Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-01-28
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT00831233
- Locations
- 🇪🇸
Fundación Puigvert, Barcelona, Spain
🇪🇸Fundacion Hospital Alcorcón, Alcorcon, Spain
🇪🇸Hospital de Basurto, Bilbao (Bizkaia), Spain
Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer
- First Posted Date
- 2008-12-25
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 24
- Registration Number
- NCT00814788
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
- Conditions
- Interventions
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2016-10-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 102
- Registration Number
- NCT00776594
- Locations
- 🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00771017
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.